Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Income from Non-Controlling Interests (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Income from Non-Controlling Interests for 8 consecutive years, with -$249469.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Non-Controlling Interests fell 284.08% year-over-year to -$249469.0, compared with a TTM value of -$468405.0 through Dec 2025, up 8.36%, and an annual FY2025 reading of -$468405.0, down 31.52% over the prior year.
  • Income from Non-Controlling Interests was -$249469.0 for Q4 2025 at Abvc Biopharma, down from -$41010.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $1.0 million in Q4 2021 and bottomed at -$316981.0 in Q4 2023.
  • Average Income from Non-Controlling Interests over 5 years is -$27925.0, with a median of -$77783.5 recorded in 2021.
  • The sharpest move saw Income from Non-Controlling Interests soared 953.06% in 2021, then plummeted 402.85% in 2024.
  • Year by year, Income from Non-Controlling Interests stood at $1.0 million in 2021, then tumbled by 64.79% to $363036.0 in 2022, then plummeted by 187.31% to -$316981.0 in 2023, then surged by 79.51% to -$64953.0 in 2024, then plummeted by 284.08% to -$249469.0 in 2025.
  • Business Quant data shows Income from Non-Controlling Interests for ABVC at -$249469.0 in Q4 2025, -$41010.0 in Q3 2025, and -$75811.0 in Q2 2025.